OrPro Therapeutics, Inc. is a San Diego preclinical-stage Johnson & Johnson JLABS alumni company addressing large unmet medical needs in acute and chronic respiratory, ophthalmology, and oncology with a cell-protective biologic drug platform based on the secreted human protein thioredoxin. Lead asset ORP100S has been shown to reduce inflammation, normalize mucociliary functions, and mitigate adverse effects of chemotherapy and radiation on stem cells in bone marrow and other sensitive organs through a novel covalent-binding mechanism that opens up disease-modifying treatment opportunities in obstructive, oxidative and inflammatory disorders, vision-threatening diseases of the retina, and cancer therapy.
